Future efforts should take advantage of these in vivo models to collect quantitative data on the molecular and cellular changes caused by VEGF/VEGFR-targeted therapies; such efforts will help identify key signaling mechanisms that affect obesity progression and response to therapies. This evidence concerns the gene VEGFA and obesity due to melanocortin 4 receptor deficiency.